Caladrius Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Mazzo
- Full Time Employees
- 27
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 110 Allen Rd Basking Ridge NJ United States of America 07920
- IPO Date
- Nov 3, 1995
- CIK
- 0000320017
- Website
- caladrius.com
- Similar Companies
- Business
- Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in Bedminster, New Jersey, primarily engaged in the development of innovative cell therapies aimed at reversing rather than managing diseases. Its core products include cell therapy candidates such as HONEDRA® (CLBS12) for critical limb ischemia, XOWNA® (CLBS16) targeting coronary microvascular dysfunction, and CLBS201, a CD34+ cell therapy designed for patients with diabetic kidney disease and pre-dialysis chronic kidney disease. The company leverages proprietary cell therapy platforms for indications in cardiovascular diseases, autoimmune diseases, and neurological disorders, with ongoing Phase II clinical trials for its lead candidates. Caladrius also operates a subsidiary, PCT, LLC, which provides development and manufacturing partnership services to the cell therapy industry, engaging in product and process development, GMP manufacturing, and regulatory support. In recent major developments, Caladrius Biosciences entered into a definitive merger agreement with Cend Therapeutics, resulting in the formation of Lisata Therapeutics, a public company focused on cancer treatment technologies, particularly solid tumor cancers including pancreatic cancer. This strategic merger, completed in late 2022, broadened Caladrius's pipeline to include Cend's investigational drug CEND-1, which is undergoing Phase 2b clinical trials for advanced pancreatic cancer in collaboration with Roche. The merger expanded the development portfolio and diversified the company's focus from primarily cardiovascular autoimmune indications to include oncology. Concurrently, the company reduced its R&D expenses and maintained a strong cash position to support pipeline advancement. Additionally, Caladrius's subsidiary PCT entered into a global collaboration and license agreement with Hitachi Chemical, including a significant equity investment, to accelerate cell therapy manufacturing capabilities and establish global leadership in this field. Founded in 2013, Caladrius Biosciences operates primarily in the United States but collaborates internationally through clinical trials and partnerships. Its business segments cover biopharmaceutical development, cell therapy product manufacturing, and strategic alliances for clinical advancement. The company continuously innovates in cell therapy technology, with multiple patent applications filed to protect its proprietary platforms. Caladrius targets markets including patients with critical ischemic conditions, autoimmune diseases, and solid tumor cancers, focusing on therapies that offer novel treatment approaches to unmet medical needs across these therapeutic areas.
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript
Caladrius Biosciences to Present at the BIO International Convention 2022
Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTYH, CLBS, IGNY, TWTR
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call Transcript
Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2021 Results - Earnings Call Transcript
Caladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern Time
Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022
Hot Penny Stocks For 2022 To Buy For Under $2
Caladrius Biosciences Inc.'s (CLBS) CEO David Mazzo on Q3 2021 Results - Earnings Call Transcript
Caladrius Biosciences to Host Third Quarter 2021 Financial Results Conference Call on Thursday, November 4th at 4:30 p.m. Eastern Time
Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2021 Results - Earnings Call Transcript
Caladrius Biosciences, Inc. (CLBS) Reports Q2 Loss, Misses Revenue Estimates
Caladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time
Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit
A Trio of Net Current Asset Value Stock Picks
Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2021 Results - Earnings Call Transcript